Growth hormone is necessary for the p53-mediated, obesity-induced insulin resistance in male C57BL/6J × CBA mice

Endocrinology

Volumn 154, Issue 11, 2013, Pages 4226-4236

  Bogazzi, Fausto ^a   Raggi, Francesco ^a   Russo, Dania ^a   Bohlooly Y, Mohammad ^b   Sardella, Chiara ^a   Urbani, Claudio ^a   Lombardi, Martina ^a   Manetti, Luca ^a   Lupi, Isabella ^a   Tornell, Jan ^c   Martino, Enio ^a  

^a UNIVERSITY OF PISA   (Italy)

^b ASTRAZENECA R AND D   (Sweden)

^c InnoExt AB   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; PROTEIN P53; STAT1 PROTEIN; STAT3 PROTEIN; STAT5B PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 1; SUPPRESSOR OF CYTOKINE SIGNALING 2; SUPPRESSOR OF CYTOKINE SIGNALING 3; SYNAPTOPHYSIN;

ACROMEGALY; ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GLUCOSE METABOLISM; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID DIET; MALE; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; WESTERN BLOTTING;

ACROMEGALY; ADIPOSE TISSUE; ANIMALS; GROWTH HORMONE; INSULIN RESISTANCE; MALE; MICE; MICE, TRANSGENIC; OBESITY; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84886464153     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2013-1220     Document Type: Article

References (47)

1. Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature. 2006;444: 840-846.
2. Schenk S, Saberi M, Olefsky JM. Insulin sensitivity: modulation by nutrients and inflammation. J Clin Invest. 2008;118: 2992-3002.
3. Dresner A, Laurent D, Marcucci M, et al. Effects of free fatty acids on glucose transport and IRS-1 associated phosphatidylinositol 3-kinase activity. J Clin Invest. 1999;103: 253-259.
4. Griffin ME, Marcucci MJ, Cline GW, et al. Free fatty acid-induced insulin resistance is associated with activation of protein kinase Cθ and alterations in the insulin signaling cascade. Diabetes. 1999;48: 1270-1274.
5. Morino K, Petersen KF, Shulman GI. Molecular mechanisms of insulin resistance in humans and their potential links with mitochondrial dysfunction. Diabetes. 2006;55(suppl 2):S9-S15.
6. Shepherd PR, Kahn BB. Glucose transporters and insulin action- implications for insulin resistance and diabetes mellitus. N Engl J Med. 1999;341: 248-257.
7. Abel ED, Peroni O, Kim JK, et al. Adipose-selective targeting of the GLUT4 gene impairs insulin action in muscle and liver. Nature. 2001;409: 729-733.
8. Furukawa S, Fujita T, Shimabukuro M, et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest. 2004;114: 1752-1761.
9. Minamino T, Orimo M, Shimizu I, et al. A crucial role for adipose tissue p53 in the regulation of insulin resistance. Nat Med. 2009; 15: 1082-1087.
10. Melmed S. Acromegaly pathogenesis and treatment. J Clin Invest. 2009;119: 3189-3202.
11. Mauras N, Haymond MW. Are the metabolic effects of GH and IGF-I separable? Growth Horm IGF Res. 2005;15: 19-27.
12. Colao A, Ferone D, Marzullo P, Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev. 2004;25: 102-152.
13. Institute of Laboratory Animal Resources. Guide for the Care and Use of Laboratory Animals. Washington, DC: National Academy Press; 1996.
14. Bohlooly-Y M, Carlson L, Olsson B, et al. Vascular function and blood pressure in GH transgenic mice. Endocrinology. 2001;142: 3317-3323.
15. Bogazzi F, Russo D, Raggi F, et al. Transgenic mice overexpressing growth hormone (GH) have reduced or increased cardiac apoptosis through activation of multiple GH-dependent or -independent cell death pathways. Endocrinology. 2008;149: 5758-5769.
16. Olsson B, Bohlooly-Y M, Fitzgerald SM, et al. Bovine growth hormone transgenic mice are resistant to diet-induced obesity but develop hyperphagia, dyslipidemia, and diabetes on a high-fat diet. Endocrinology. 2005;146: 920-930.
17. Murphy PJ, Galigniana MD, Morishima Y, et al. Pifithrin-α inhibits p53 signaling after interaction of the tumor suppressor protein with hsp90 and its nuclear translocation. J Biol Chem. 2004;279: 30195-30201.
18. Sutton GM, Trevaskis JL, Hulver MW, et al. Diet-genotype interactions in the development of the obese, insulin-resistant phenotype of C57BL/6J mice lacking melanocortin-3 or -4 receptors. Endocrinology. 2006;147: 2183-2196.
19. Bonzon-Kulichenko E, Fernandez-Agullo T, Molto E, et al. Regulation of insulin-stimulated glucose uptake in rat white adipose tissue upon chronic central leptin infusion: effects on adiposity. Endocrinology. 2011;152: 1366-1377.
20. Verschuren L, Kooistra T, Bernhagen J, et al.MIFdeficiency reduces chronic inflammation in white adipose tissue and impairs the development of insulin resistance, glucose intolerance, and associated atherosclerotic disease. Circ Res. 2009;105: 99-107.
21. Bogazzi F, Ultimieri F, Raggi F, et al. Peroxisome proliferator activated receptor γ expression is reduced in the colonic mucosa of acromegalic patients. J Clin Endocrinol Metab. 2002;87: 2403-2406.
22. Vousden KH, Ryan KM. p53 and metabolism. Nat Rev Cancer. 2009;9: 691-700.
23. Cheung EC, Vousden KH. The role of p53 in glucose metabolism. Curr Opin Cell Biol. 2010;22: 186-191.
24. Puzio-Kuter AM. The role of p53 in metabolic regulation. Genes Cancer. 2011;2;85-391.
25. Horn HF, Vousden KH. Coping with stress: multiple ways to activate p53. Oncogene. 2007;26: 1306-1316.
26. Vousden KH, Prives C. Blinded by the light: the growing complexity of p53. Cell. 2009;137: 413-431.
27. Sablina AA, Budanov AV, Ilyinskaya GV, Agapova LS, Kravchenko JE, Chumakov PM. The antioxidant function of the p53 tumor suppressor. Nat Med. 2005;11: 1306-1313.
28. Jones RG, Plas DR, Kubek S, et al. AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol Cell. 2005;18: 283-293.
29. Buzzai M, Jones RG, Amaravadi RK, et al. Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res. 2007;67: 6745-6752.
30. List EO, Berryman DE, Funk K, et al. The role of GH in adipose tissue: lessons from adipose-specific GH receptor gene-disrupted mice. Mol Endocrinol. 2013;27: 524-535.
31. Shah A, Mehta N, Reilly MP. Adipose inflammation, insulin resistance, and cardiovascular disease. J Parenter Enteral Nutr. 2008; 32: 638-644.
32. Ueki K, Kondo T, Kahn CR. Suppressor of cytokine signaling 1 (SOCS-1) and SOCS-3 cause insulin resistance through inhibition of tyrosine phosphorylation of insulin receptor substrate proteins by discrete mechanisms. Mol Cell Biol. 2004;24: 5434-5446.
33. Lumeng CN, Saltiel AR. Inflammatory links between obesity and metabolic disease. J Clin Invest. 2011;121: 2111-2117.
34. Starr R, Willson TA, Viney EM, et al.Afamily of cytokine-inducible inhibitors of signalling. Nature. 1997;387: 917-921.
35. Lagathu C, Bastard JP, Auclair M, Maachi M, Capeau J, Caron M. Chronic interleukin-6 (IL-6) treatment increased IL-6 secretion and induced insulin resistance in adipocyte: prevention by rosiglitazone. Biochem Biophys Res Commun. 2003;14: 372-379.
36. Senn JJ, Klover PJ, Nowak IA, et al. Suppressor of cytokine signaling- 3 (SOCS-3), a potential mediator of interleukin-6-dependent insulin resistance in hepatocytes. J Biol Chem. 2003;278: 13740-13746.
37. Tiret L, Godefroy T, Lubos E, et al. Genetic analysis of the interleukin- 18 system highlights the role of the interleukin-18 gene in cardiovascular disease. AtheroGene Investigators. Circulation. 2005 112: 643-650.
38. Fain JN. Release of interleukins and other inflammatory cytokines by human adipose tissue is enhanced in obesity and primarily due to the nonfat cells. Vitam Horm. 2006;74: 443-477.
39. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-α: direct role in obesity-linked insulin resistance. Science. 1993;259: 87-91.
40. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-α in human obesity and insulin resistance. J Clin Invest. 1995;95: 2409-2415.
41. Rui L, Yuan M, Frantz D, Shoelson S, White MF. SOCS-1 and SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRS1 and IRS2. J Biol Chem. 2002;277: 42394-42398.
42. Vijayakumar A,WuY, Sun H, et al. Targeted loss ofGHRsignaling in mouse skeletal muscle protects against high-fat diet-induced metabolic deterioration. Diabetes. 2012;61: 94-103.
43. Laron Z, Avitzur Y, Klinger B. Insulin resistance in Laron syndrome (primary insulin-like growth factor I deficiency) and effect of IGF-I replacement therapy. J Pediatr Endocrinol Metab. 1997;10(suppl 1): 105-115.
44. Zhou Y, Xu BC, Maheshwari HG, et al. A mammalian model for Laron syndrome produced by targeted disruption of the mouse growth hormone receptor/binding protein gene (the Laron mouse). Proc Natl Acad Sci USA. 1997;94: 13215-13220.
45. Dominici FP, Arostegui Diaz G, Bartke A, Kopchick JJ, Turyn D. Compensatory alterations of insulin signal transduction in liver of growth hormone receptor knockout mice. J Endocrinol. 2000;166: 579-590.
46. Li J, Ghiani CA, Kim JY, et al. Inhibition of p53 transcriptional activity: a potential target for future development of therapeutic strategies for primary demyelination. J Neurosci. 2008;28: 6118-6127.
47. Kaplan SL. Hormone regulation of growth and metabolic effects of growth hormone. In: Kostyo JL, ed. Hormone Control of Growth. New York: Oxford University Press; 1999: 129-143.